Treatment References

Anolik R, Mometasone Furoate Nasal Spray with Loratidine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(3):264–71.

Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy. 2010;40(2):242–50.

Berger W, Hampel Jr F, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:375–81.

Berger WE, Shah S, Liberman P, Hadley J, Price D, Munzel U et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjected with rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179–85.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63(Suppl. 86):8–160.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al. MACVIA clinical decision algorithm in allergic rhinitis in adolescents and adults. J Allergy Clin Immunol. 2016;138(2):367–74.

Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393–400.

Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62:17–25.

Canonica GW,Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.Clin Exp Immunol.. 2009;158(3):260–71.

Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219–24.

Ciebiada M, Gorska Ciebiada M, Barylski M, Kmiecik T, Gorski P. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25(1):e1–6.

Ciprandi G, Incorvaia C, Scurati S, Puccinelli P, Soffia S, Frati F et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27:1005–11.

Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol. 2000;84(5):533–8.

Demoly P, Allaery AA, Lecasble M, PRAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002;57:546–54.

Diamant Z, van der Molen T. Treating asthma: is there a place for leukotriene receptor antagonists? Respir Med.. 2005;99:655–62.

Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:259–67.

Dollner R, Larsen PL, Dheyauldeen S, Steinsvåg S. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu. Allergy Rhinol. 2017;8:e148–6.

Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D et al. Treatments for Seasonal Allergic Rhinitis. AHRQ Publication No. 13-EHC098-EF. Rockville, MD: Agency for Healthcare Research and Quality.

Hampel FC, Ratner PH, van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168–73.

Handelman NI, Friday GA, Schwartz HJ, Kuhn FS, Lindsay DE, Koors PG et al. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 1977;59:237–42.

Harrow B, Sedaghat AR, Caldwell-Tarr A, Dufour R. A comparison of healthcare resource utilisation and costs for patients with allergic rhinitis on single-product or free-combination therapy of intranasal steroids and intranasal antihistamines. J Manag Care Spec Pharm. 2016;22:1426–36.

Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold – high cost to society. Allergy. 2010;65:776–83.

Johnson DA, Hricik JG. The pharmacology of α-adrenergic decongestants. Pharmacothrapy. 1993;13(6 pt2):110S–115S.

Kaiser HB, Findlay SR, Geogitis JW, Grossman J, Ratner PH, Tinkelman DG et al. The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated perennial allergic rhinitis. Allergy Asthma Proc. 1998;19(1):23–9.

Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36:40–7.

Lejeune M, Lefebvre PP, Delvenne P, El-Shazly AE. Nasal sodium cromoglicate (Lomusol) modulates the early phase reaction of mild to moderate persistent allergic rhinitis in patients mono-sensitized to house dust mite: a preliminary study. Int Immunopharmacol. 2015;26(1):272–6.

Liu G, Zhou X, Chen J, Liu F. Oral antihistamines alone vs in combination with leukotriene receptor antagonists for allergic rhinitis: a meta-analysis. Otolaryngol Head Neck Surg. 2018. DOI: 10.1177/0194599817752624. [Epub ahead of print].

Martin BG, Andrews CP, van Bavel JH, Hampel FC, Klein KC, Prillaman BA et al. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol. 2006;96(6):851–7.

Meltzer EO, NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther. 2002;24:942–52.

Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33:324–332.

Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369–77.

Meltzer EO, Ratner PH, McGraw T. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomised, placebo-controlled trial in allergic rhinitis patients. Ann Allergy Asthma Immunol. 2016;116(1):66–71.

Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682–8.

Min Y-G. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2010;2(2):65–76.

Moscato G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, Quirce S et al. EAACI position paper on occupational rhinitis. Respir Res. 2009;10:16.

Mullol J. A survey of the burden of allergic rhinitis in Spain. J Investig Allergol Clin Immunol. 2009;19(1):27–34.

Navarro A, Valero A, Rosales MJ, Mullol J. Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011;21(5):363–9.

Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int. 2014;23(8):282–319.

Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc. 2000;21(1):15–20.

Pohl W, Kaulsay R, Stjärne P. Real life effectiveness of MP-AzeFlu® in persistent allergic rhinitis, assessed by visual analogue scale and endoscopy: pooled data from Austria, Ireland and Sweeden. Presented at the Symposium of Experimental Rhinology and Immunology of the Nose Congress 2017, 30 March–01 April 2017. Dusseldorf, Germany.

Potter PC. Effectiveness and safety of new-generation antihistamines in allergenic rhinitis and urticaria. SA Fam Prac. 2004;47(1):24–8. Available at

Price D, Scadding G, Ryan D Bachert C, Canonica GW, Mullol J et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39.

Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62(Suppl 85):9–16.

Stjärne P, Pohl W, Kaulsay R. MP-AzeFlu® improves sleep quality in patients with persistent allergic rhinitis: data from Austria, Ireland and Sweden. Presented at the European Academy of Allergy and Clinical Immunology Congress 2017, 17–21 June 2017. Helsinki, Finland. P0653

Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, Bosnic-Anticevich S. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Res Pract 2017;3:8. DOI 10.1186/s40733–017-0036–z.

Tran NP, Vickery J, Blaiss MS. Management of rhinitis: Allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3(3):148–56.

Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. Ann Intern Med. 2017;167:876–81.